Gossamer Bio, Inc. (GOSS) Stock Profile — Insider Trades & Financials

Revenue$13.8M

Net Income-$47.2M

EPS$-0.54

Market Cap$81.1M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Faheem Hasnain

CEO & Executive Director

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Founded: 2015
Employees: 162
Headquarters

⚡

Core Efficiency

ROE?

38.48%

ROA?

-27.42%

D/E Ratio?

-2.40

Op. Margin?

-333.64%

📊

Profitability Ratios

Net Margin?

-342.33%

Loading company sections...

Gossamer Bio, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness